Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
Amylyx Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities and Carry Forward Securities
| Security type | Security class title | Fee calculation or carry forward rule | Amount registered | Proposed maximum offering price per share | Proposed maximum aggregate offering price(1)(2) | Fee rate | Amount of registration fee (3) | |||||||||
| Newly Registered Securities | ||||||||||||||||
Fees to Be Paid | Equity | Common Stock, par value $0.0001 per share | 457(o) | — | — | $41,054,984 | 0.0001102 | $4,524.26 | ||||||||
Fees Previously Paid | — | — | — | — | — | — | — | — | ||||||||
| Carry Forward Securities | ||||||||||||||||
Carry Forward Securities | — | — | — | — | — | — | — | — | ||||||||
| Total Offering Amounts | $41,054,984 | $4,524.26 | ||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||
| Total Fee Offsets | — | |||||||||||||||
| Net Fee Due (4) | $4,524.26 | |||||||||||||||
| (1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). |
| (2) | Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase additional shares. |
| (3) | Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. |
| (4) | The Registrant previously registered securities having a proposed maximum aggregate offering price of $205,275,000 on its Registration Statement on Form S-1 (File No. 333-267730), which was declared effective by the Securities and Exchange Commission on October 6, 2022. In accordance with Rule 462(b) under the Securities Act, an additional number of securities having a proposed maximum offering price of $41,054,984 is hereby registered, which includes securities issuable upon the exercise of the underwriters’ option to purchase additional shares. |
